101 related articles for article (PubMed ID: 1764273)
21. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M;
Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935
[TBL] [Abstract][Full Text] [Related]
22. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
23. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
Robak T; Lech-Maranda E; Janus A; Blonski J; Wierzbowska A; Gora-Tybor J
Leuk Lymphoma; 2007 Jun; 48(6):1092-101. PubMed ID: 17577772
[TBL] [Abstract][Full Text] [Related]
24. Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study.
Spiers AS; Weens JH; Rowe JM; Smith TJ; Horton J; Gordon LI; Glick JH
Am J Clin Oncol; 1991 Dec; 14(6):519-25. PubMed ID: 1720279
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
26. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
27. [Multiple drug therapy in Hodgkin's disease, lymphosarcoma and reticulosarcoma].
Con I; Daiber A; Donoso A; Osorio G; Mora F
Rev Med Chil; 1972 Apr; 100(4):408-13. PubMed ID: 4557485
[No Abstract] [Full Text] [Related]
28. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
[TBL] [Abstract][Full Text] [Related]
29. [Early phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
Tominaga N; Teshima H; Hiraoka A; Masaoka T; Ariyoshi Y; Suzuki H; Kimura I; Ohnoshi T; Hayashi K; Arima T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2441-6. PubMed ID: 1952963
[TBL] [Abstract][Full Text] [Related]
30. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma.
Hosein PJ; Craig MD; Tallman MS; Boccia RV; Hamilton BL; Lewis JJ; Lossos IS
Am J Hematol; 2012 Jan; 87(1):111-4. PubMed ID: 22081459
[No Abstract] [Full Text] [Related]
31. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas.
Lossos IS; Paltiel O; Polliack A
Leuk Lymphoma; 1999 Mar; 33(1-2):155-60. PubMed ID: 10194133
[TBL] [Abstract][Full Text] [Related]
32. [COBDP combination chemotherapy in the treatment of malignant lymphoma--report on 64 patients].
Jin XQ
Zhonghua Zhong Liu Za Zhi; 1991 Jul; 13(4):295-8. PubMed ID: 1806351
[TBL] [Abstract][Full Text] [Related]
33. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas.
Tura S; Mazza P; Gherlinzoni F; Zinzani PL; Poletti G; Visani G; Lemoli RM; Cavo M; Galieni P; Tassi C
Cancer Chemother Pharmacol; 1989; 23(2):123-5. PubMed ID: 2910510
[TBL] [Abstract][Full Text] [Related]
35. [Late phase II study of MST-16 (sobuzoxane) efficacy for malignant lymphoma].
Masaoka T; Kageyama T; Tatsumi N; Akasaka K; Yonezawa T; Sugiyama H; Kitani T; Yasunaga K; Horiuchi A; Nakayama S
Gan To Kagaku Ryoho; 1992 Mar; 19(3):339-47. PubMed ID: 1543360
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma.
Song DY; Jones RJ; Welsh JS; Haulk TL; Korman LT; Noga S; Goodman S; Herman M; Mann R; Marcellus D; Vogelsang G; Ambinder RF; Abrams RA
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):166-71. PubMed ID: 12909229
[TBL] [Abstract][Full Text] [Related]
37. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
Bezwoda W; Rastogi RB; Erazo Valla A; Diaz-Maqueo JC; Pavlovsky S; Morioka H; Resegotti L; Rueckle H; Somoza N; Moreno-Nogueira JA
Eur J Cancer; 1995 Jun; 31A(6):903-11. PubMed ID: 7646919
[TBL] [Abstract][Full Text] [Related]
38. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
[TBL] [Abstract][Full Text] [Related]
39. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY.
Avalos BR; Klein JL; Kapoor N; Tutschka PJ; Klein JP; Copelan EA
Bone Marrow Transplant; 1993 Aug; 12(2):133-8. PubMed ID: 8401359
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]